Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page
- Check6 days agoChange DetectedThe screenshots depict the same history page with only minor UI/organizational changes and a new version entry added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision: v3.4.2 was added. The funding lapse notice and the Revision: v3.4.1 note were removed.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status. Updated the revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe history page now includes a glossary display option and color-coded legends for additions and deletions, and revision notes have been updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check42 days agoChange DetectedThe record history now shows a new revision entry (v3.3.4) and the previous revision (v3.3.3) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry 'Revision: v3.3.3' was added to the Record History, and the 'HHS Vulnerability Disclosure' item and the older 'Revision: v3.3.2' entry were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.